Neimeth International Pharmaceuticals Plc is set to access the capital market to execute a N20 billion fundraising programme approved by shareholders in 2025, as the company seeks to consolidate its return to profitability and fund a new phase of capacity expansion.
This disclosure was made by the Managing Director/CEO, Pharm. Valentine Okelu, during the firm’s 2026 annual media briefing ahead of the Annual General Meeting (AGM).
The capital raise is aimed at strengthening operations, refinancing obligations, and positioning the firm for long-term growth across African markets.
The initiative follows a decisive financial turnaround, with management asserting that recent earnings credibility and operational stability provide the foundation for new capital inflows and investor confidence.
Neimeth’s leadership emphasized that the N20 billion capital raise will support facility upgrades, scale production, and position the company for regional expansion.
The funds will also stabilise the balance sheet after legacy debt restructuring, which temporarily increased finance costs.
“At our Annual General Meeting on June 23, 2025, shareholders approved a N20 billion capital raise. This capital will be deployed to complete expansion projects, strengthen working capital, reduce financing costs, enhance production capacity, and consolidate our growth momentum.”
“We intend to access the capital market at the appropriate time to execute part of this approved raise. The company views fundraising as essential to sustaining growth, enhancing competitiveness, and doubling earnings over the medium term,” Okelu stated.
The capital raise is a strategic move to underpin operational resilience and long-term shareholder value creation.
